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EDITORIAL
The Future of f3-Lactam Antibiotics
Historical landmarks of major technical dis-
coveries are continuously reevaluated by newer
research technologies, and this principle also holds
true with antibiotics. Thus, recent fluorescence
studies have identified the presence of tetracycline
in Nubian bones recovered from a Sudanese
cemetery [1]. This discovery predates the an-
tibiotic era by more than 1,500 years and will be
hard to top. As far as (3-lactam compounds are
concerned, their official history is just a little over
50 years old; they can be traced back to Fleming's
genial interpretation of the interaction between
the mold Penicillium and Staphylococcus aureus
in 1928 [2]. Since then, microbiologists and
organic chemists have purified and synthesized
thousands of variants of the original molecule,
and sizable numbers of them have found clinical
application. Thus, the "(3-lactam-tree" summa-
rized in 1979 [3] has continued its dramatic
growth, and two years later it already shows a
large number of new twigs budding off, including
the oxa-(3-lactam compound moxalactam. But just
as trees have to be regularly inspected and pruned,
it is our task to cast sometimes a critical view on
this (3-lactam family to eliminate redundant or ob-
solete compounds and to foster the development
of novel agents' with hitherto unknown biological
or biochemical properties.
Of the many present and future aspects of the
(3-lactam compounds, this discussion will concen-
trate merely on two groups of problems that will,
in my opinion, receive growing attention in the
future. First, it is more than likely that new
(3-lactam compounds that are active against resis-
tant nosocomial gram-negative organisms will be
developed that will exhibit antibacterial activity at
concentrations as low as those encountered for the
action of penicillin G against group A streptococ-
ci. Such a development will certainly decrease the
need for and use of more toxic antibiotics in non-
compromised hosts; whether their use as single
drugs in compromised hosts will become common
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medical practice is, and probably will remain, an
unsettled question. To replace some of the more
toxic compounds, however, these new (3-lactam
antibiotics will have to keep the basic toxicologic
and pharmacologic properties of the penicillin G
molecule.
Second, further rapid progress can be foreseen
in the evaluation of the properties and investiga-
tion of the modes of action of the (3-lactam anti-
biotics. Determination of bacteriostatic and
bactericidal end points (MICs and MBCs, respec-
tively) against pathogens seems indeed to be a
crude and controversial way of assessing new anti-
biotics. New approaches, such as identification of
the species specificity of the various penicillin-
binding proteins, of the enzyme systems suscepti-
ble to these antibiotics, and of possible inactivat-
ing enzyme systems, as well as demonstration of
the early biochemical and morphologic changes
occurring prior to cell death, will help to discover
more active substances and lead to the identifica-
tion of new and as yet unknown modulating ef-
fects of the (3-lactam antibiotics on the pathogeni-
city of microorganisms.
Development of (3-Lactam Antibiotics Active
Against Gram-Negative Organisms
Since (3-lactamase-negative gram-positive or-
ganisms are inhibited and killed by concentrations
of penicillin G ranging from 0.01 to 0.05 ug/ml, it
seems unrealistic to expect any future compound
to have a higher efficacy against these organisms
[4]. This expectation is only partly true for semi-
synthetic compounds such as the isoxazolylpenicil-
lins, which exert their antibacterial effects on most
(3-lactamase-producing staphylococci at micro-
gram concentrations [5] and are of unpredictable
efficacy against the many emerging, resistant
strains of Staphylococcus epidermidis. Moreover,
the failure rate for severe staphylococcal infec-
tions is still considerable and might be partly
related to the problem of tolerance of these
organisms to a variety of bactericidal antibiotics.
Thus, there is still room for improvement at this
end of the antibacterial spectrum, and more bac-
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Figure 1. Structure of (top) penicillin and its basic fermentation product, 6-amino-penicillanic acid, and (bottom)
cephalosporin C and its basic fermentation product, 7-amino-cephalosporanic acid. R, RI, and R2 indicate variable
side chains.
tericidal antistaphylococcal fJ-Iactam compounds
with low toxicity are awaited with interest.
What about the activity of fJ-Iactam compounds
against gram-negative bacilli? With the fermenta-
tion product 6-aminopenicillanic acid as a starting
point (figure 1, top), major changes in the side
chain (R) of the penicillin G molecule were
necessary over the last decades to expand the anti-
microbial spectrum of the fJ-Iactam compounds to
include the common gram-negative enteric orga-
nisms. It must be remembered, however, that
these compounds, which are mostly ampicillin
analogues and esters (table 1), exert their activity
at concentrations often 10-100 times higher than
those of penicillin G. This observation is even
more striking when one considers the newer a-car-
boxylpenicillins and acylamino analogues of am-
picillin - notably, carbenicillin, ticarcillin, azlocil-
lin, and piperacillin - which are characterized
biochemically by further modifications of the side
chain and bacteriologically by their expanded
spectrum, including many Pseudomonas species,
at the cost of very high MICs.
In striking analogy with the penicillins, a variety
of semisynthetic derivatives of the closely related
compound cephalosporin C and its nucleus (figure
Table 1. Modifications of the penicillin G molecule for production of representative penicillins with an expanded
activity against gram-negative bacilli.
Modification
Antibiotic
Ampicillins
Carbenicillins
Ureidopenicillins
Piperacillin
• See figure 1 for location of R.
Side chain (R)·
a-Amino-benzyl-
a-Carboxyl-benzyl-
Acyl-ureido-
Piperazine-amino-benzyl-
/3-Lactam ring
No
No
No
No
Thiazolidine ring
No
No
No
No
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Table 2. Modifications of the cephalosporin C molecule for production of representative first-, second-, and third-
generation cephalosporins.
Antibiotic group, examples
First generation
Cephalothin, cephapirin, and cephalexin
Second generation
Cefamandole, cefazolin, and cefuroxime
Cefoxitin
Third generation
Cefotaxime, cefsulodin, and cefoperazone
Modification
Side chain"
Rl R2 f3- Lactam ring
Yes Yes No
Yes Yes No
No Yes Yes
Yes Yes! No
Dihydrothiazine ring
No
No
No
No
• See figure 1 for location of Rl and R2.
t Large heterocyclic side chain.
1, bottom), 7-aminocephalosporanic acid, has
been developed. The first- and second-generation
cephalosporins are characterized biochemically by
modifications of both side chains (Rl and R2),
with the exception of cefoxitin [6, 7]. These later
cephalosporins differ among themselves by minor
variations in antibacterial spectrum and pharma-
cokinetic properties (table 2). Third-generation
cephalosporins still contain the 7-aminocepha-
losporanic acid nucleus, but it is now flanked by
two expanded, heterocyclic, bulky side chains.
These newer modifications have resulted con-
comitantly in an impressive expansion of the an-
tibacterial spectrum to include commonly resis-
tant, often nosocomial, gram-negative organisms,
as well as in a dramatic decrease in the MICs
of the drugs for most of the gram-negative
organisms.
Research in the field of (3-lactam compounds
has led to other recent interesting developments.
First, the question can be asked whether the in-
tegrity of the thiazolidine ring is a prerequisite for
antibacterial action or interaction with bacterial
substrates. That this integrity is not necessary is
shown by the compound clavulanic acid and its
many derivatives - short-chain (3-lactams that
have the S atom of the thiazolidine ring replaced
by an 0 atom and have little antibiotic activity but
possess potent inhibitory effects on most of the
microbial (3-lactamases (table 3). Olivanic acid
derivatives - i.e., penicillin analogues in which the
heterocyclic S atom has been replaced by a C
atom - are another interesting group of (3-
lactamase inhibitors. Thienamycin and its
derivatives are chemically related to the olivanic
acids, but the former exhibit strong antibacterial
activity against a large variety of gram-negative
and gram-positive, aerobic and anaerobic orga-
nisms. Newer synthetic compounds also include
sulfone derivatives of penicillanic acid, a group of
potent irreversible inhibitors of (3-lactamases. Last
but not least, moxalactam represents probably the
boldest modification of the initial (3-lactam struc-
ture, which produced a combination of chemical
and microbiologic properties found individually in
many of the various (3-lactam compounds present-
ly available. It is of great interest to note that the
MICs of these new compounds for certain gram-
negative organisms are in the range of those
reported 50 years ago with penicillin G for suscep-
Table 3. Modifications of the fJ-Iactam structure for production of new f3-lactam antibiotics and related compounds.
Modifications in
Antibiotic or compound
Clavulanic acid and derivatives
Olivanic acid and derivatives
Thienamycin and derivatives
Penicillanic acid and ~erivatives
Moxalactam and derivatives
Side chains
Short
Variable
Variable
Absent
Large
f3-Lactam ring
No
No
No
No
No
Thiazolidine ring
S replaced by 0
S replaced by C
S replaced by C
S replaced by sulfone
Dihydrothiazine ring; S replaced by 0
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tible grarn-posiuve organisms. By analogy, one
can therefore conclude that it will be difficult to
improve the antibacterial activity of such com-
pounds against gram-negative organisms. If
proved effective in clinical trials, these compounds
could well simplify our future approach to anti-
bacterial therapy for hospital-acquired infections.
Assessment of the Biological Activities of
{3-Lactam Compounds
Antibiotic activity is customarily expressed either
in terms of MICs and MBCs in an in vitro micro-
biologic system or in terms of efficacy in an ex-
perimental animal model. Extrapolation from
such data to infections in humans is not always
possible and is often conceptually incorrect be-
cause a variety of biophysical, microbiologic, and
specific host factors, which are operative during
infections, are not adequately assessed by these
conventional susceptibility studies or may show
important variations from species to species.
Finally, we still do not know how bacteria are
killed by antibiotics in the human host, whether
host defense mechanisms are potentiated when in
contact with altered bacteria, and whether locally
persisting bacteria will be recognized and elim-
inated by the host immune system.
Fortunately, more refined measurements of an-
timicrobial activity and exciting new discoveries
allow us now to put into proper perspective some
events that are induced by these compounds and
occur prior to microbial death. As we shall see,
these events can now be recognized and followed
by biochemical and morphologic techniques and
might by themselves alter the handling of the
"sick" microorganism by the host. For instance, a
refined view of the mode of action of some
{3-lactam compounds has emerged through the
demonstration of their protein-binding sites at the
cell membrane level [8] and of their induction of
morphologic changes in susceptible bacteria [9].
These modifications, observed either in specific
intracellular structures or at the cell membrane
level before or concomitant with the first expres-
sion of their antibacterial activity, can be used,
among other approaches, as new screening tests
for novel antibacterial compounds.
Along the same line of thought, evidence is ac-
cumulating that within the human body concen-
trations of an antibiotic too low to kill micro-
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organisms might still render them more suscepti-
ble to nonspecific or specific host clearance
mechanisms. This concept emerges from several
studies with subinhibitory concentrations of an-
tibiotics defined so far by morphologic criteria,
turbidimetry, time-killing curves, synergistic
studies, or by determination of the recovery
period after exposure to antibiotic [10-12]. Be-
cause {3-lactam derivatives primarily alter the
bacterial cell wall structure at subinhibitory con-
centrations, it follows that bacteria exposed to
minimal amounts of antibiotics will present an
altered surface to the host, and therefore a
modified relation between these two types of cells
is produced. Thus, bacteria exposed to sub-
minimal concentrations of {3-lactam or other anti-
biotics show suppressed adherence to human cells,
decreased mannose-binding activity, decreased
binding to uroepithelial cells, and increased en-
gulfment by phagocytic cells [10-12]. Several of
these mechanisms are presently believed to be im-
portant pathogenic factors in human disease. If
indeed the pathogenicity of the organisms and/or
their handling by the host can be altered by such
compounds at concentrations that are impercepti-
ble by conventional microbiologic techniques, new
light will be shed on basic questions such as the
blood and tissue levels of antibiotic that are re-
quired to control infection. These observations
might also help to develop new compounds that
alter the binding of potential pathogens to
mucosal surfaces or phagocytic cells without ex-
erting an antibacterial effect on the physiologic
flora of the host, which is another way to treat or
prevent infection.
Conclusions
The history and the present state of the {3-lactam
antibiotics look impressive; so does the future.
Whereas little is to be expected from the develop-
ment of new compounds even more active against
gram-positive non-{3-lactamase-producing orga-
nisms, there is a need for new antibacterial sub-
stances that show better bactericidal activity
against {3-lactamase-producing gram-positive
organisms and particularly against gram-negative
bacilli. The potency of present and future com-
pounds against most gram-negative organisms will
probably reach the levels described by Fleming [2]
for penicillin G, at the expense of a loss in their
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antimicrobial spectrum against gram-positive or-
ganisms. Finally, it is conceivable that new com-
pounds of the (J-Iactam group, used at low con-
centrations, may alter the bacterial surface of
pathogens to render them more susceptible to anti-
bacterial clearing mechanisms in humans. Just by
following these two lines of thought, I suspect that
we have many years of exciting basic and clinical
research ahead of us.
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